175 related articles for article (PubMed ID: 23619976)
1. EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Neumann F; Kaddu-Mulindwa D; Widmann T; Preuss KD; Held G; Zwick C; Roemer K; Pfreundschuh M; Kubuschok B
Cancer Immunol Immunother; 2013 Jul; 62(7):1211-22. PubMed ID: 23619976
[TBL] [Abstract][Full Text] [Related]
2. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
[TBL] [Abstract][Full Text] [Related]
3. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.
Herr W; Ranieri E; Olson W; Zarour H; Gesualdo L; Storkus WJ
Blood; 2000 Sep; 96(5):1857-64. PubMed ID: 10961887
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
5. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.
Kubuschok B; Pfreundschuh M; Breit R; Hartmann F; Sester M; Gärtner B; König J; Murawski N; Held G; Zwick C; Neumann F
Hum Gene Ther; 2012 Dec; 23(12):1224-36. PubMed ID: 22966960
[TBL] [Abstract][Full Text] [Related]
6. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma.
Riener MO; Wild PJ; Soll C; Knuth A; Jin B; Jungbluth A; Hellerbrand C; Clavien PA; Moch H; Jochum W
Int J Cancer; 2009 Jan; 124(2):352-7. PubMed ID: 18942708
[TBL] [Abstract][Full Text] [Related]
7. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
[TBL] [Abstract][Full Text] [Related]
8. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
10. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
11. Differential antigen presentation by heat-treated peripheral blood mononuclear cells and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL): heated EBV-LCL present alloantigen and soluble antigen but are deficient in the stimulation of autologous EBV-LCL primed T cells.
Mandell RB; Hank JA; Chen BP; Robins HI; Sondel PM
Hum Immunol; 1987 Jul; 19(3):163-77. PubMed ID: 3040644
[TBL] [Abstract][Full Text] [Related]
12. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
[TBL] [Abstract][Full Text] [Related]
13. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
14. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
[TBL] [Abstract][Full Text] [Related]
15. [Expression of multiple cancer-testis antigen genes in non-small cell lung cancer treated by chemotherapy prior surgery].
Wang Y; Liang Z; Yuan YH; Han Y; Liu YX; Liu N; Chen YT; Ritter G; Old LJ; Zhang LJ
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(6):464-8. PubMed ID: 15061963
[TBL] [Abstract][Full Text] [Related]
16. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Adair SJ; Hogan KT
Cancer Immunol Immunother; 2009 Apr; 58(4):589-601. PubMed ID: 18791715
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.
Schirmer U; Fiegl H; Pfeifer M; Zeimet AG; Müller-Holzner E; Bode PK; Tischler V; Altevogt P
BMC Cancer; 2013 Mar; 13():156. PubMed ID: 23530769
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]